MEK kinase-2 inhibitors belong to a distinct chemical class of compounds that have garnered considerable attention due to their significant role in modulating cellular processes. These inhibitors are designed to specifically target and bind to MEK kinase-2, a crucial enzyme within the MAPK signaling pathway. This pathway plays an essential role in transmitting extracellular signals to the nucleus, thereby regulating various cellular activities, including proliferation, differentiation, survival, and apoptosis. MEK kinase-2 inhibitors function by obstructing the enzymatic activity of MEK kinase-2, thereby disrupting the cascade of downstream events that it triggers. This inhibition ultimately impacts the transmission of growth and survival signals, potentially leading to alterations in cellular behavior. Structurally, MEK kinase-2 inhibitors possess distinct molecular features that enable them to interact selectively with the active site of the MEK kinase-2 enzyme. These compounds often exhibit a specific arrangement of functional groups that are essential for binding and inhibitory activity.
The development of MEK kinase-2 inhibitors involves a meticulous design process aimed at achieving optimal binding affinity and selectivity, thereby minimizing off-target effects. Researchers in the field of chemical biology and drug discovery continue to refine the structural characteristics of these inhibitors, leveraging advanced computational modeling and experimental techniques to enhance their potency and specificity. In summary, MEK kinase-2 inhibitors represent a notable class of compounds recognized for their ability to modulate the MAPK signaling pathway by targeting the enzyme MEK kinase-2. These inhibitors operate by hindering the enzymatic function of MEK kinase-2 and subsequently disrupting the downstream cellular responses driven by this pathway. The molecular design of MEK kinase-2 inhibitors is carefully tailored to facilitate specific interactions with the enzyme's active site, ensuring effective inhibition while minimizing unintended effects on other cellular processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Trametinib is an allosteric inhibitor of MEK1/MEK2 that reduces tumor growth in mouse xenograft models. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Investigated for various cancers, including pediatric neurofibromatosis type 1-related plexiform neurofibromas. | ||||||
BAY 869766 | 923032-37-5 | sc-364427 sc-364427A | 5 mg 10 mg | $240.00 $420.00 | 1 | |
Studied for potential applications in melanoma and other cancers. | ||||||
AS703026 | 1236699-92-5 | sc-364412 sc-364412A | 5 mg 10 mg | $80.00 $130.00 | ||
Investigational inhibitor for solid tumors and hematological malignancies. | ||||||
TAK-733 | 1035555-63-5 | sc-364630 sc-364630A | 5 mg 10 mg | $340.00 $640.00 | 1 | |
Experimental MEK kinase-2 inhibitor explored for its potential in cancer research. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
Investigational inhibitor by Array BioPharma developed for potential cancer therapy. | ||||||
LY3009120 | 1454682-72-4 | sc-507538 | 5 mg | $125.00 | ||
Selective MEK kinase-2 inhibitor studied in research and clinical settings for cancer research. | ||||||